search
Back to results

The Effect of IV Cangrelor and Oral Ticagrelor Study

Primary Purpose

Acute Coronary Syndrome (ACS), High On-treatment Platelet Reactivity (HTPR), Microvascular Obstruction (MVO)

Status
Completed
Phase
Phase 4
Locations
United Kingdom
Study Type
Interventional
Intervention
Cangrelor
Ticagrelor
Sponsored by
The Royal Wolverhampton Hospitals NHS Trust
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Acute Coronary Syndrome (ACS) focused on measuring Adenosine Diphosphate, Cardiovascular Magnetic Resonance (CMR), Index of microvascular resistance (IMR), Vasodilator stimulated phosphoprotein phosphorylation (VASP), Pharmacodynamic, Antiplatelet, Myocardial Infarction (MI), Cangrelor, Ticagrelor, Coronary artery bypass graft (CABG), Primary percutaneous coronary intervention (PPCI)

Eligibility Criteria

18 Years - undefined (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  • Patients presenting with STEMI eligible for PPCI
  • Able to give verbal assent pre procedure and written consent following the procedure.
  • Age ≥18 years
  • No contraindication to Cangrelor or Ticagrelor
  • Thienopyridine naïve

If a patient gives verbal assent but is unable to provide a written consent at a later stage due to incapacitation, presumed consent will be continued. The reasons why a patient becomes incapacitated and becomes unable to provide a written consent will be recorded during data collection.

Exclusion Criteria:

  • Be unable to provide verbal assent and written consent
  • Allergic to Aspirin or any of the P2Y12 antagonists in the trial
  • Have pre-existing cardiogenic shock
  • Previous myocardial infarction
  • Have a concurrent septic or inflammatory disease e.g. rheumatoid arthritis, lupus, and pneumonia.
  • Already taking a P2Y12 inhibitor
  • Known bleeding diathesis
  • Significant active bleeding
  • History of intracranial hemorrhage
  • Patients who are being treated with formal anticoagulation (Vitamin K antagonist, Factor II or Xa inhibitors) or have an indication for anticoagulation during the first four hours of the study period. Example is patients known to have atrial fibrillation, pulmonary embolism or deep vein thrombosis.
  • Known severe renal dysfunction requiring renal replacement therapy.

Sites / Locations

  • The Royal Wolverhampton NHS Trust

Arms of the Study

Arm 1

Arm 2

Arm Type

Active Comparator

Active Comparator

Arm Label

Oral Ticagrelor

Intravenous Cangrelor

Arm Description

Patients in the oral Ticagrelor arm will receive Ticagrelor at a loading dose of 180mg followed by maintenance dose of 90mg twice daily for 12 months.

Patients in the intravenous Cangrelor arm will receive Cangrelor as an initial bolus dose given as per body weight followed by an intravenous infusion for no longer than three hours, they will then switch to oral Ticagrelor given at maintenance dose of 90mg twice daily for 12 months

Outcomes

Primary Outcome Measures

Degree of platelet inhibition measured with VerifyNow(R) system, rapid platelet function analyser and also VASP flow cytometry at infarct vessel open time (also known as balloon time)

Secondary Outcome Measures

Index of Microvascular Resistance (IMR) measurement using pressure wire studies immediately following the PPCI procedure.
Measurement of thrombolysis in myocardial infarction (TIMI) flow grade using TIMI Frame Count
ST Segment Resolution by ECG
Infarct size by Peak Troponin post PPCI

Full Information

First Posted
April 5, 2016
Last Updated
October 29, 2018
Sponsor
The Royal Wolverhampton Hospitals NHS Trust
search

1. Study Identification

Unique Protocol Identification Number
NCT02733341
Brief Title
The Effect of IV Cangrelor and Oral Ticagrelor Study
Official Title
The Effect of Intravenous Cangrelor and Oral Ticagrelor on Platelets, the Microcirculation and Myocardial Damage in Patients Admitted With STEMI Treated by Primary Percutaneous Coronary Intervention: A Randomized Controlled Pilot Trial
Study Type
Interventional

2. Study Status

Record Verification Date
October 2018
Overall Recruitment Status
Completed
Study Start Date
July 21, 2016 (Actual)
Primary Completion Date
October 1, 2018 (Actual)
Study Completion Date
October 1, 2018 (Actual)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
The Royal Wolverhampton Hospitals NHS Trust

4. Oversight

Data Monitoring Committee
Yes

5. Study Description

Brief Summary
Major heart attacks are caused by a number of factors, the two major of which are furring up of a coronary artery with atheroma and then sudden clot formation on this area leading to a blockage and interruption of blood flow. The clots that lead to heart attacks are largely made of clotting blood cells (platelets) that in health repair blood vessels and inhibit spontaneous bleeding. One of the main treatment strategies for heart attacks is to make these cells less "sticky". Aspirin is a main stay of anti-platelet treatment in the United Kingdom (UK) and in addition one of three other oral antiplatelet agents acting on the same platelet activation pathway (P2Y12 receptor) is licensed for use. When a patient is admitted with a major heart attack, they are treated with emergency primary percutaneous coronary intervention (PPCI) a technique where a wire and balloon are used to reopen the coronary artery and then usually a stent (a slotted metal tube) is placed to keep the artery open. Aspirin and one of the P2Y12 inhibitor agents are given to prevent further clots and all have been shown to reduce negative events following heart attacks and angioplasty with stent insertion. There are increasing data, including from our own institution, showing that in the setting of heart attacks, the oral P2Y12 inhibitors are poorly absorbed and have little effect at the time of most need, i.e. soon after dosing while the primary PCI is being performed. All three current P2Y12 inhibitor agents are taken in tablet form immediately before the emergency PPCI procedure. It appears that in healthy stable patients these agents take at least 30 min to 2 hours to have an adequate effect. In heart attack patients the angioplasty procedure is usually performed well within this timescale. Furthermore, patients who are having a heart attack do not have normal drug absorption with blood being diverted away from the stomach and gut activity being suppressed by other drugs such as morphine. In this current study, patients with major heart attacks will be given our standard oral agent, Ticagrelor, or the newer intravenous agent Cangrelor prior to PPCI.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Acute Coronary Syndrome (ACS), High On-treatment Platelet Reactivity (HTPR), Microvascular Obstruction (MVO), ST-segment Elevation Myocardial Infarction (STEMI), Thrombolysis in Myocardial Infarction (TIMI), Unstable Angina (UA)
Keywords
Adenosine Diphosphate, Cardiovascular Magnetic Resonance (CMR), Index of microvascular resistance (IMR), Vasodilator stimulated phosphoprotein phosphorylation (VASP), Pharmacodynamic, Antiplatelet, Myocardial Infarction (MI), Cangrelor, Ticagrelor, Coronary artery bypass graft (CABG), Primary percutaneous coronary intervention (PPCI)

7. Study Design

Primary Purpose
Treatment
Study Phase
Phase 4
Interventional Study Model
Parallel Assignment
Masking
None (Open Label)
Allocation
Randomized
Enrollment
100 (Actual)

8. Arms, Groups, and Interventions

Arm Title
Oral Ticagrelor
Arm Type
Active Comparator
Arm Description
Patients in the oral Ticagrelor arm will receive Ticagrelor at a loading dose of 180mg followed by maintenance dose of 90mg twice daily for 12 months.
Arm Title
Intravenous Cangrelor
Arm Type
Active Comparator
Arm Description
Patients in the intravenous Cangrelor arm will receive Cangrelor as an initial bolus dose given as per body weight followed by an intravenous infusion for no longer than three hours, they will then switch to oral Ticagrelor given at maintenance dose of 90mg twice daily for 12 months
Intervention Type
Drug
Intervention Name(s)
Cangrelor
Intervention Type
Drug
Intervention Name(s)
Ticagrelor
Primary Outcome Measure Information:
Title
Degree of platelet inhibition measured with VerifyNow(R) system, rapid platelet function analyser and also VASP flow cytometry at infarct vessel open time (also known as balloon time)
Time Frame
up to 24-36 hours post dosing
Secondary Outcome Measure Information:
Title
Index of Microvascular Resistance (IMR) measurement using pressure wire studies immediately following the PPCI procedure.
Time Frame
1 hour
Title
Measurement of thrombolysis in myocardial infarction (TIMI) flow grade using TIMI Frame Count
Time Frame
3 Months
Title
ST Segment Resolution by ECG
Time Frame
90-120 minutes post PPCI
Title
Infarct size by Peak Troponin post PPCI
Time Frame
24-36 hours

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: Patients presenting with STEMI eligible for PPCI Able to give verbal assent pre procedure and written consent following the procedure. Age ≥18 years No contraindication to Cangrelor or Ticagrelor Thienopyridine naïve If a patient gives verbal assent but is unable to provide a written consent at a later stage due to incapacitation, presumed consent will be continued. The reasons why a patient becomes incapacitated and becomes unable to provide a written consent will be recorded during data collection. Exclusion Criteria: Be unable to provide verbal assent and written consent Allergic to Aspirin or any of the P2Y12 antagonists in the trial Have pre-existing cardiogenic shock Previous myocardial infarction Have a concurrent septic or inflammatory disease e.g. rheumatoid arthritis, lupus, and pneumonia. Already taking a P2Y12 inhibitor Known bleeding diathesis Significant active bleeding History of intracranial hemorrhage Patients who are being treated with formal anticoagulation (Vitamin K antagonist, Factor II or Xa inhibitors) or have an indication for anticoagulation during the first four hours of the study period. Example is patients known to have atrial fibrillation, pulmonary embolism or deep vein thrombosis. Known severe renal dysfunction requiring renal replacement therapy.
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
James Cotton
Organizational Affiliation
The Royal Wolverhampton NHS Trust
Official's Role
Principal Investigator
Facility Information:
Facility Name
The Royal Wolverhampton NHS Trust
City
Wolverhampton
ZIP/Postal Code
WV10 0QP
Country
United Kingdom

12. IPD Sharing Statement

Plan to Share IPD
No
Citations:
PubMed Identifier
31129911
Citation
Ubaid S, Ford TJ, Berry C, Murray HM, Wrigley B, Khan N, Thomas MR, Armesilla AL, Townend JN, Khogali SS, Munir S, Martins J, Hothi SS, McAlindon EJ, Cotton JM. Cangrelor versus Ticagrelor in Patients Treated with Primary Percutaneous Coronary Intervention: Impact on Platelet Activity, Myocardial Microvascular Function and Infarct Size: A Randomized Controlled Trial. Thromb Haemost. 2019 Jul;119(7):1171-1181. doi: 10.1055/s-0039-1688789. Epub 2019 May 26.
Results Reference
derived

Learn more about this trial

The Effect of IV Cangrelor and Oral Ticagrelor Study

We'll reach out to this number within 24 hrs